Oncology Portfolios And Biosimilars Will Fuel Global Healthcare Expansion
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 2 Analysts
Published
17 Aug 25
Updated
20 Aug 25
AnalystHighTarget's Fair Value
₹1,200.00
29.0% undervalued intrinsic discount20 Aug
₹851.95
1Y
19.1%7D
-6.0%